Cancer needs a quick response time, too
The majority of cancer types have no recommended screening and can go undetected for too long.1,2 Adding the Galleri® multi-cancer early detection test can help fill that gap by screening for some of the deadliest cancers including those we don’t have screening tests for today like pancreatic, lymphoma and head and neck, all through a simple blood draw.
Sensitivity in study participants with - Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV). Lymphoma: 56.3% overall (27.3% stage I; 58.3% stage II; 71.7% stage III; 60.9% stage IV) . Head and neck cancer: 85.7% overall (63.2% stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV).
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Galleri was studied in a population age of 50 and older and studies specific to firefighters have not been conducted. Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a cancer signal detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
Galleri should be used in addition to provider recommended screenings.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Galleri was studied in a population age of 50 and older and studies specific to firefighters have not been conducted. Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a cancer signal detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.
Galleri should be used in addition to provider recommended screenings.
Nearly 15,000 firefighters tested across over 90 departments in the United States
“The Galleri testing event for our firefighters went like clockwork. I did a lot of research in selecting the Galleri test for our department. With the help of physician leaders in firefighter cancer and occupational medicine, I felt confident that this test was the best. I looked at other options, but none have the supporting clinical evidence that GRAIL and Galleri did. I dug deep into the science of the test, so we were ready when one of our team members had a cancer signal detected. What this test provided our firefighters and our department was priceless, and our firefighters say the same to me. They were very grateful, too.”
Duane S. Daggers Jr.
Battalion Chief
City of Chesapeake Fire Department
“Cancer is the leading cause of death among firefighters, and as early detection and preventative measures become more prevalent, so too must our vigilance in sharing those resources with the firefighters who have a nearly 15% higher risk of dying from cancer than the general population. Galleri is a leading partner in this life-saving work, and we at the Orange County Fire Authority aim to leverage their innovative cancer screening test to help our firefighters live long, healthy lives.”
Brian Fennessy
Fire Chief
Orange County Fire Authority
“The Professional Firefighters of Massachusetts (PFFM) implemented the Galleri test for thousands of firefighters at various events we've hosted. We are very pleased with the experience of implementing the test and what it has provided for our firefighters. The Galleri test helped by screening for some of the most deadly cancers that do not have other screenings. The bottom line for me was that screening with the Galleri test meant we could cast a wider net by adding it to single cancer screening tests, which I believe is an incredible advancement for firefighter health.”
Richard D. MacKinnon Jr.
President
Professional Firefighters of Massachusetts
“Offering the Galleri test to our firefighters was an easy process once we secured funding. The online order request tool was simple to use and the onsite testing process was quick and smooth. We had almost 90% of those eligible take the test, which speaks to the value our team felt, too. Cancer is personal to so many of us in this line of work, and unfortunately we can tend to be reactive when it comes to our health. But this is one way that we can help our firefighters be more proactive in screening for cancer.”
Jayson Nicewarner
Lieutenant
Morgantown WV Fire Department
Adding the Galleri test to guideline-recommended screening increases the chance of early cancer detection through screening.
Improve the chances for early cancer detection.
Based on modeled data, the Galleri test has the potential to shift cancer detection to earlier stages, showing a 26% reduction in 5-year cancer-related mortality.3
Claims data analysis shows that the Galleri test can potentially detect a signal shared by 98% of individuals’ diagnosed cancer types.4
Early-stage cancer was an average of 3X less expensive to treat vs late-stage in the first year after diagnosis.5
Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.
*Galleri has not been tested in a firefighter-specific population.
The Galleri story
-
Protecting Those Who Protect Us: Firefighter Leaders on the Importance of Cancer Screening
-
Leading by Example: Why Firefighter Leaders Take the Galleri Test
-
Chicago Fire Department
-
Patient testimonial: Valerie
Cancer Signal Detected
-
Patient testimonial: Roger
Cancer Signal Detected
How Galleri Works
All cells, healthy and cancerous, release DNA into the bloodstream. But DNA from cancer cells is different from DNA from healthy cells. Using next-generation DNA sequencing, machine learning, and AI, the Galleri test can detect a cancer signal in the blood and predict the tissue or organ associated with the cancer signal.
Validated by rigorous clinical studies, the Galleri test detects abnormalities in the methylation patterns of cell-free DNA (cfDNA) that could indicate the presence of cancer. When used alongside guideline recommended screening tests, the Galleri test can improve the chance of finding a cancer signal early.
The studies that support Galleri performance included more than 140 clinical study sites, including
Get Started
Fill out this form and we’ll reach out to discuss how the Galleri test could positively impact your organization
By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.
Frequently Asked Questions
The Galleri test identifies DNA in the bloodstream shed by cancer cells at the time of your blood draw. If a cancer signal is detected, Galleri results include a prediction of the organ or tissue type associated with the cancer signal to help your healthcare provider guide next steps.
The Galleri test should be used in addition to guideline-recommended cancer screening, such as mammography, colonoscopy, prostate specific antigen (PSA) or cervical cancer screening. Galleri is recommended for use in adults with an elevated risk of cancer, such as those aged 50 or older.
Your GRAIL team can work with you to plan an onsite event where an ordering provider orders the test where participants have their blood drawn.
We also have the ability to offer the test through telemedicine, and an independent healthcare provider will review the request and order the test, if appropriate. The test is prescription only.
The Galleri test detects a cancer signal shared by more than 50 cancers. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Recommended cancer screening tests such as colonoscopy or mammograms are commonly used and have been shown to reduce cancer deaths. The Galleri test is intended to be used in addition to and not replace these tests. Missing recommended screening or ignoring symptoms could lead to a delayed diagnosis of cancer. Ask your healthcare provider about what cancer screening tests are right for you.
All individuals who receive a Cancer Signal Detected result on their Galleri test receive a phone call from a healthcare provider to explain the results and ensure the employee has a primary care physician (PCP) with whom the results can be shared. A GRAIL patient advocate can connect the the individual’s PCP with expert peer-to-peer consultation services regarding next steps for diagnostic testing. If they do not currently have a PCP, the patient advocate will provide them with local, in-network primary care navigation support. Once a PCP is found, the patient advocate can provide connections to expert peer-to-peer physician support and conducts ongoing follow-up with the individual to confirm the appropriate next steps are taken towards diagnostic evaluation.
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
- U.S. Preventive Services Task Force (USPSTF) grades A,B,C recommended cancer screening tests. https://uspreventiveservicestaskforce.org/uspstf/topic_search_results
- Siegel RL et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
- Hubbell E, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-468. DOI: doi.org/10.1158/1055-9965.EPI-20-1134
- Analysis of MarketScan claims database completed by GRAIL, Inc., July 2022. Data on file GA-2022-0085.
- Reddy SR, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. DOI: doi.org/10.1080/03007995.2022.2047536.